Cancer drug research has been aided tremendously by the recent identification of the role of several kinases in signal transduction pathways involved in the progression of many cancers including several types of leukemias, prostate, ovarian, brain, breast and lung carcinomas. The emergence of novel inhibitors of these kinases in phase I, II and III clinical trials against cancer is indicative of the importance of receptor-mediated signaling in modern therapeutic interventions against cancer. The primary objective of our laboratory is to develop new models designed to enhance the efficacy of signal transduction inhibitors in the treatment of refractory tumours.

Bertrand J. Jean-Claude, Ph.D., CRS-CIHR Scholar, Director

The Cancer Drug Research Laboratory
Royal Victoria Hospital/McGill University Health Center
687 Pine Avenue West Rm M-719
Montreal, PQ H3A 1A1
Tel: 514-843-1231 ext: 35841